Nexalin Technology Q3 Earnings Forecast Cut by Maxim Group

Nexalin Technology, Inc. (NASDAQ:NXL) – Equities researchers at Maxim Group cut their Q3 2026 earnings per share estimates for Nexalin Technology in a research note issued to investors on Monday, October 12th. Maxim Group analyst A. Vendetti now anticipates that the company will post earnings per share of ($2.91) for the quarter, down from their previous estimate of ($2.70). The consensus estimate for Nexalin Technology’s current full-year earnings is ($11.40) per share. Maxim Group also issued estimates for Nexalin Technology’s Q4 2026 earnings at ($2.34) EPS, FY2026 earnings at ($11.42) EPS and FY2027 earnings at ($7.55) EPS.

Nexalin Technology (NASDAQ:NXL) last announced its earnings results on Wednesday, August 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.00) by $2.89. Nexalin Technology had a negative return on equity of 278.24% and a negative net margin of 4,141.94%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.09 million.

Several other equities analysts have also commented on the stock. Weiss Ratings lowered shares of Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 25th. Zacks Research raised shares of Nexalin Technology to a “hold” rating in a research report on Thursday, October 1st. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce”.

Nexalin Technology Stock Down 4.9%

NASDAQ NXL opened at $2.51 on Thursday. The firm’s fifty day simple moving average is $6.51 and its two-hundred day simple moving average is $10.21. Nexalin Technology has a 12-month low of $2.38 and a 12-month high of $50.70.

Institutional Trading of Nexalin Technology

An institutional investor recently bought a new position in Nexalin Technology stock. PEAK6 LLC purchased a new position in Nexalin Technology, Inc. (NASDAQ:NXL) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 240,210 shares of the company’s stock, valued at approximately $79,000. PEAK6 LLC owned approximately 1.09% of Nexalin Technology as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 0.65% of the company’s stock.

Nexalin Technology Company Profile

Nexalin Technology, Inc is a medical device company focused on developing noninvasive neurostimulation technologies for mental health and neurological applications. Its products are designed to deliver cranial electrotherapy stimulation (CES), a form of electrical stimulation intended to influence brain activity without the use of pharmaceutical drugs or invasive procedures.

The company’s product portfolio includes the Gen-2 and Gen-3 Nexalin devices, which use proprietary waveform technology and electrodes placed on the head to administer treatment.